Published in BMJ on January 08, 2010
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89
Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet (2014) 3.53
Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med (2013) 3.25
Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care (2012) 3.24
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes (2015) 2.87
National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med (2014) 2.61
American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc (2013) 1.99
The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care (2015) 1.93
Geographic variation in pharmacotherapy decisions for U.S. Medicare enrollees with diabetes. J Diabetes Complications (2012) 1.84
Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med (2015) 1.77
Hypoglycemia and cardiovascular risks. Diabetes Care (2011) 1.74
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care (2012) 1.67
The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care (2011) 1.66
Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care (2011) 1.49
Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care (2011) 1.49
HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study. BMJ (2015) 1.48
Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med (2011) 1.48
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 1.43
HbA1c and all-cause mortality risk among patients with type 2 diabetes. Int J Cardiol (2015) 1.42
Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD. Diabetologia (2015) 1.41
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ (2016) 1.40
Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med (2011) 1.39
Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol (2010) 1.37
Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hospitalized patients. Diabetes Care (2012) 1.31
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol (2011) 1.21
Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues. Diabetes Care (2010) 1.20
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol (2015) 1.17
Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care (2012) 1.15
Point: Intensive glycemic control and mortality in ACCORD--a chance finding? Diabetes Care (2010) 1.13
Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther (2011) 1.13
The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract (2010) 1.13
Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care (2012) 1.12
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes (2012) 1.07
Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care (2012) 1.07
Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival. Am J Cardiol (2012) 1.05
Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care (2011) 1.03
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol (2013) 1.00
Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation (2010) 1.00
No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia (2011) 0.99
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci (2013) 0.99
Type 2 diabetes mellitus--current therapies and the emergence of surgical options. Nat Rev Endocrinol (2011) 0.97
Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol (2013) 0.97
Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials. Rev Diabet Stud (2011) 0.97
Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care (2012) 0.96
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol (2016) 0.96
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care (2016) 0.95
Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol (Lausanne) (2012) 0.95
Safety and efficacy of modern insulin analogues. Diabetes Metab J (2013) 0.95
No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J (2011) 0.95
Participant characteristics and study features associated with high retention rates in a longitudinal investigation of type 1 diabetes mellitus. Clin Trials (2012) 0.95
Continuous Glucose Monitoring Systems: A Review. Diagnostics (Basel) (2013) 0.94
Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. Patient Prefer Adherence (2014) 0.93
Insulin: potential negative consequences of early routine use in patients with type 2 diabetes. Diabetes Care (2011) 0.93
Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Intern Med (2016) 0.91
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry. Cardiovasc Diabetol (2011) 0.91
Should A1C targets be individualized for all people with diabetes? Arguments for and against. Diabetes Care (2011) 0.91
Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci (2014) 0.90
Hypoglycemia in older people - a less well recognized risk factor for frailty. Aging Dis (2015) 0.89
Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. Circulation (2010) 0.89
Cardiovascular disease in diabetes: where does glucose fit in? J Clin Endocrinol Metab (2011) 0.89
Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes. Diabetes Metab J (2016) 0.89
Glycemic control and cardiovascular disease: what's a doctor to do? Curr Diab Rep (2012) 0.89
Hypoglycemia as a driver of cardiovascular risk in diabetes. Curr Atheroscler Rep (2013) 0.89
Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes. J Gen Intern Med (2016) 0.89
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. Diabetes Care (2015) 0.89
Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab (2012) 0.88
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes. Korean J Intern Med (2014) 0.88
Causative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetes. World J Diabetes (2015) 0.87
Hidden complexities in assessment of glycemic outcomes: are quality rankings aligned with treatment? Diabetes Care (2010) 0.87
Hypoglycemia associated with hospitalization and adverse events in older people: population-based cohort study. Diabetes Care (2013) 0.87
Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One (2011) 0.86
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag (2014) 0.86
Prediction of 90-day mortality in patients without diabetes by severe hypoglycemia: blood glucose level as a novel marker of severity of underlying disease. Acta Diabetol (2014) 0.86
Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY) (2014) 0.85
Association between impaired cardiovascular autonomic function and hypoglycemia in patients with type 1 diabetes. Diabetes Care (2014) 0.85
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol (2013) 0.84
Hypoglycemia in Type 2 Diabetes--More Common Than You Think: A Continuous Glucose Monitoring Study. J Diabetes Sci Technol (2015) 0.84
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis (2013) 0.83
Low HbA1c and Increased Mortality Risk-is Frailty a Confounding Factor? Aging Dis (2015) 0.83
The effect of frailty should be considered in the management plan of older people with Type 2 diabetes. Future Sci OA (2016) 0.83
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging (2013) 0.83
Hypoglycemia in Patients with Diabetes and Renal Disease. J Clin Med (2015) 0.83
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care (2016) 0.82
Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions. BMJ Open Diabetes Res Care (2016) 0.81
Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry. BMC Endocr Disord (2014) 0.81
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol (2016) 0.81
Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial. Diabetes Care (2014) 0.80
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
New visual acuity charts for clinical research. Am J Ophthalmol (1982) 12.72
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med (2004) 10.35
The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum (1953) 10.06
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med (2007) 7.90
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.49
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care (2003) 3.08
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J (2005) 2.71
Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation (2005) 2.69
Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes (2008) 2.04
NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. J Electrocardiol (1992) 1.59
Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med (1997) 1.50
Hypoglycemia preceding fatal car collisions. Diabetes Care (2006) 1.36
Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med (1999) 1.29
Comparisons of confidence intervals for attributable risk. Biometrics (1981) 1.09
Hypoxia/hypoglycemia preconditioning prevents the loss of functional electrical activity in organotypic slice cultures. Brain Res (2005) 1.06
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci (2006) 6.61
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care (2009) 5.41
Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care (2005) 5.38
A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab (2008) 4.97
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract (2011) 4.69
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.68
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care (2002) 4.46
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Recommendations for management of diabetes during Ramadan. Diabetes Care (2005) 4.27
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med (2010) 4.03
Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02
Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation (2007) 3.99
American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract (2009) 3.96
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.49
The T1D Exchange clinic registry. J Clin Endocrinol Metab (2012) 3.45
Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc Natl Acad Sci U S A (2007) 3.40
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 3.25
Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation (2009) 3.23
Cognitive dysfunction and diabetes mellitus. Endocr Rev (2008) 3.17
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
The lifestyle interventions and independence for elders (LIFE) pilot study: design and methods. Contemp Clin Trials (2005) 2.79
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
CaMKII determines mitochondrial stress responses in heart. Nature (2012) 2.63
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
The Lifestyle Interventions and Independence for Elders Study: design and methods. J Gerontol A Biol Sci Med Sci (2011) 2.26
Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci (2002) 2.22
Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. Am J Clin Nutr (2002) 2.21
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc (2002) 2.13
Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care (2004) 2.12
The effect of randomization to weight loss on total mortality in older overweight and obese adults: the ADAPT Study. J Gerontol A Biol Sci Med Sci (2010) 2.12
Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care (2013) 2.03
Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci (2009) 2.02
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab (2013) 1.92
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care (2003) 1.91
The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol (2007) 1.85
Reliability of the 400-m usual-pace walk test as an assessment of mobility limitation in older adults. J Am Geriatr Soc (2004) 1.84
The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab (2004) 1.84
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Nutrition principles and recommendations in diabetes. Diabetes Care (2004) 1.78
Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation (2009) 1.77
Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes (2008) 1.74